Literature DB >> 15762886

Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

R Garg1, S K Gupta, P Tripathi, S Naik, S Sundar, A Dube.   

Abstract

Development of an effective immunoprophylactic agent for visceral leishmaniasis (VL) has become imperative due to the increasing number of cases of drug resistance and relapse. Live and killed whole parasites as well as fractionated and recombinant preparations have been evaluated for vaccine potential. However, a successful vaccine against the disease has been elusive. Because protective immunity in human and experimental leishmaniasis is predominantly of the Th1 type, immunogens with Th1 stimulatory potential would make good vaccine candidates. In the present study, the integral membrane proteins (IMPs) and non-membranous soluble proteins (NSPs), purified from promastigotes of a recent field isolate, Leishmania donovani stain 2001, were evaluated for their ability to induce cellular responses in cured patients (n = 9), endemic controls (n = 5) of visceral leishmaniasis (VL) and treated hamsters (n = 10). IMPs and NSPs induced significant proliferative responses (SI 6.3 +/- 4.1 and 5.6 +/- 2.3, respectively; P < 0.01) and IFN-gamma production (356.3 +/- 213.4 and 294.29 +/- 107.6 pg/ml, respectively) in lymphocytes isolated from cured VL patients. Significant lymphoproliferative responses against IMPs and NSPs were also noticed in cured Leishmania animals (SI 7.2 +/- 4.7 &amp; 6.4 +/- 4.1, respectively; P < 0.01). In addition, significant NO production in response both IMPs and NSPs was also noticed in macrophages of hamsters and different cell lines (J774A-1 and THP1). These results suggest that protective, immunostimulatory molecules are present in the IMP and NSP fractions, which may be exploited for development of a subunit vaccine for VL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762886      PMCID: PMC1809348          DOI: 10.1111/j.1365-2249.2005.02745.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex.

Authors:  A Jardim; D L Tolson; S J Turco; T W Pearson; R W Olafson
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

2.  Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages.

Authors:  F Y Liew; Y Li; D Moss; C Parkinson; M V Rogers; S Moncada
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

3.  Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

Authors:  L P Kahl; C A Scott; R Lelchuk; G Gregoriadis; F Y Liew
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

4.  Characterization of integral membrane proteins of Leishmania major by Triton X-114 fractionation and analysis of vaccination effects in mice.

Authors:  P J Murray; T W Spithill; E Handman
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.

Authors:  C L Jaffe; N Rachamim; R Sarfstein
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

6.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

7.  Cytokine patterns in the pathogenesis of human leishmaniasis.

Authors:  C Pirmez; M Yamamura; K Uyemura; M Paes-Oliveira; F Conceição-Silva; R L Modlin
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Human T cell responses to gp63, a surface antigen of Leishmania.

Authors:  D M Russo; J M Burns; E M Carvalho; R J Armitage; K H Grabstein; L L Button; W R McMaster; S G Reed
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

9.  Mapping human T cell epitopes in leishmania gp63. Identification of cross-reactive and species-specific epitopes.

Authors:  D M Russo; A Jardim; E M Carvalho; P R Sleath; R J Armitage; R W Olafson; S G Reed
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

10.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.

Authors:  P Scott; P Natovitz; R L Coffman; E Pearce; A Sher
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  21 in total

1.  Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Pragya Misra; Sujoy Dutta; Bala Krishna Kolli; Sharad Sharma; Kwang Poo Chang; Anuradha Dube
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

2.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.

Authors:  Anil Kumar Jaiswal; Prashant Khare; Sumit Joshi; Pramod Kumar Kushawaha; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

5.  Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

Authors:  P Khare; A K Jaiswal; C D P Tripathi; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2016-04-27       Impact factor: 4.330

6.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

7.  Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism.

Authors:  Dinesh Chandra; Sita Naik
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

8.  Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Authors:  Prashant Khare; Anil Kumar Jaiswal; Chandra Dev Pati Tripathi; Sumit Joshi; Shyam Sundar; Anuradha Dube
Journal:  Parasitol Res       Date:  2013-12-27       Impact factor: 2.289

9.  Immunologic indicators of clinical progression during canine Leishmania infantum infection.

Authors:  Paola M Boggiatto; Amanda E Ramer-Tait; Kyle Metz; Erin E Kramer; Katherine Gibson-Corley; Kathleen Mullin; Jesse M Hostetter; Jack M Gallup; Douglas E Jones; Christine A Petersen
Journal:  Clin Vaccine Immunol       Date:  2009-12-23

Review 10.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.